Literature DB >> 31519778

White matter hyperintensity burden in patients with ischemic stroke treated with thrombectomy.

Grégoire Boulouis1, Nicolas Bricout1, Wagih Benhassen1, Marc Ferrigno1, Guillaume Turc1, Martin Bretzner1, Joseph Benzakoun1, Pierre Seners1, Thomas Personnic1, Laurence Legrand1, Denis Trystram1, Christine Rodriguez-Regent1, Andreas Charidimou1, Natalia S Rost1, Serge Bracard1, Charlotte Cordonnier1, Catherine Oppenheim1, Olivier Naggara1, Hilde Henon1.   

Abstract

INTRODUCTION: To determine the influence of white matter hyperintensity (WMH) burden on functional outcome, rate of symptomatic intracerebral hemorrhage (sICH), and procedural success in patients with acute ischemic stroke (AIS) treated by mechanical thrombectomy (MT) with current stentriever/aspiration devices.
METHODS: Patients with AIS due to large vessel occlusion (LVO) from the Thrombectomie des Artères Cérébrales (THRACE) trial and prospective cohorts from 2 academic comprehensive stroke centers treated with MT were pooled and retrospectively analyzed. WMH volumes were obtained by semiautomated planimetric segmentation and tested in association with the rate of favorable outcome (90-day functional independence), substantial recanalization after MT, and sICH.
RESULTS: A total of 496 participants were included between 2015 and 2018 (50% female, mean age 68.1 ± 15.0 years). Overall, 434 (88%) patients presented with detectable WMH (mean ± SD 4.93 ± 7.7). Patients demonstrated increasingly worse outcomes with increasing WMH volumes (odds ratio [aOR]1.05 per 1-cm3 increase for unfavorable outcome, 95% confidence interval [CI] 1.01-1.06, p = 0.014). Fifty-seven percent of patients in the first quartile of WMH volume vs 28% in the fourth quartile demonstrated favorable outcome (p < 0.001). WMH severity was not associated with sICH rate (aOR 0.99, 95% CI 0.93-1.04, p = 0.66), nor did it influence recanalization success (aOR 0.99, 95% CI 0.96-1.02, p = 0.84).
CONCLUSION: Our study provides evidence that in patients with AIS due to LVO and high burden of WMH as assessed by pretreatment MRI, the safety and efficacy profiles of MT are similar to those in patients with lower WMH burden and confirms that they are at higher risk of unfavorable outcome. Because more than a quarter of patients in the highest WMH quartile experienced favorable 3 months outcome, WMH burden may not be a good argument to deny MT. CLINICALTRIALSGOV IDENTIFIER: NCT01062698.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 31519778      PMCID: PMC6815208          DOI: 10.1212/WNL.0000000000008317

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Determinants of Intracranial Hemorrhage Occurrence and Outcome after Neurothrombectomy Therapy: Insights from the Solitaire FR With Intention For Thrombectomy Randomized Trial.

Authors:  R Raychev; R Jahan; D Liebeskind; W Clark; R G Nogueira; J Saver
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-27       Impact factor: 3.825

2.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

3.  Setting a gold standard for quantification of leukoaraiosis burden in patients with ischemic stroke: the Atherosclerosis Risk in Communities Study.

Authors:  Natalia S Rost; Saloomeh Sadaghiani; Alessandro Biffi; Kaitlin M Fitzpatrick; Lisa Cloonan; Jonathan Rosand; Dean K Shibata; Thomas H Mosley
Journal:  J Neurosci Methods       Date:  2014-01-15       Impact factor: 2.390

4.  Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.

Authors:  M E Gurol; M C Irizarry; E E Smith; S Raju; R Diaz-Arrastia; T Bottiglieri; J Rosand; J H Growdon; S M Greenberg
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

5.  Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).

Authors:  Andreas Charidimou; Marco Pasi; Marco Fiorelli; Sara Shams; Rüdiger von Kummer; Leonardo Pantoni; Natalia Rost
Journal:  Stroke       Date:  2016-08-04       Impact factor: 7.914

6.  Elderly patients are at higher risk for poor outcomes after intra-arterial therapy.

Authors:  Ronil V Chandra; Thabele M Leslie-Mazwi; Daniel C Oh; Zeshan A Chaudhry; Brijesh P Mehta; Natalia S Rost; James D Rabinov; Joshua A Hirsch; R Gilberto González; Lee H Schwamm; Albert J Yoo
Journal:  Stroke       Date:  2012-06-28       Impact factor: 7.914

7.  Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke.

Authors:  E M Arsava; R Rahman; J Rosand; J Lu; E E Smith; N S Rost; A B Singhal; M H Lev; K L Furie; W J Koroshetz; A G Sorensen; H Ay
Journal:  Neurology       Date:  2009-04-21       Impact factor: 9.910

8.  Leukoaraiosis predicts parenchymal hematoma after mechanical thrombectomy in acute ischemic stroke.

Authors:  Zhong-Song Shi; Yince Loh; David S Liebeskind; Jeffrey L Saver; Nestor R Gonzalez; Satoshi Tateshima; Reza Jahan; Lei Feng; Paul M Vespa; Sidney Starkman; Noriko Salamon; J Pablo Villablance; Latisha K Ali; Bruce Ovbiagele; Doojin Kim; Fernando Viñuela; Gary R Duckwiler
Journal:  Stroke       Date:  2012-05-10       Impact factor: 7.914

9.  Leukoaraiosis and increased cerebral susceptibility to ischemia: lack of confounding by carotid disease.

Authors:  Ursula G Schulz; Basil E Grüter; Dennis Briley; Peter M Rothwell
Journal:  J Am Heart Assoc       Date:  2013-08-20       Impact factor: 5.501

10.  Predictors of Outcome and Hemorrhage in Patients Undergoing Endovascular Therapy with Solitaire Stent for Acute Ischemic Stroke.

Authors:  Shaowei Jiang; Aihua Fei; Ya Peng; Jun Zhang; You-Ran Lu; Hai-Rong Wang; Miao Chen; Shuming Pan
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

View more
  11 in total

1.  White Matter Disease and Outcomes of Mechanical Thrombectomy for Acute Ischemic Stroke.

Authors:  E A Mistry; A M Mistry; T Mehta; N Arora; A K Starosciak; F D L R La Rosa; J E Siegler; S E Kasner; R Chitale; M Fusco; M Froehler; S Yaghi; M Schrag; P Khatri
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

2.  White matter burden does not influence the outcome of mechanical thrombectomy.

Authors:  Laura Mechtouff; Norbert Nighoghossian; Camille Amaz; Marielle Buisson; Yves Berthezène; Laurent Derex; Elodie Ong; Omer Faruk Eker; Tae-Hee Cho
Journal:  J Neurol       Date:  2019-11-08       Impact factor: 4.849

3.  Pre-procedural predictive factors of symptomatic intracranial hemorrhage after thrombectomy in stroke.

Authors:  Laura Venditti; Olivier Chassin; Claire Ancelet; Nicolas Legris; Mariana Sarov; Bertrand Lapergue; Cristian Mihalea; Augustin Ozanne; Sophie Gallas; Jonathan Cortese; Vanessa Chalumeau; Leon Ikka; Jildaz Caroff; Julien Labreuche; Laurent Spelle; Christian Denier
Journal:  J Neurol       Date:  2021-01-03       Impact factor: 4.849

4.  Effect of Cerebral Small Vessel Disease Burden on Outcomes in Patients With Acute Ischemic Stroke Receiving Endovascular Treatment.

Authors:  Hao Huang; Weifeng Zong; Xu Tong; Xue Tian; Anxin Wang; Baixue Jia; Jing Zhao; Lingshan Wu; Xirui Zhou; Yinping Guo; Yi Zhang; Zhiyuan Yu; Yilong Wang; Yongjun Wang; Xiang Luo; Zhongrong Miao
Journal:  Front Aging Neurosci       Date:  2022-06-13       Impact factor: 5.702

5.  Small vessel disease and collaterals in ischemic stroke patients treated with thrombectomy.

Authors:  Géraud Forestier; Rémi Agbonon; Nicolas Bricout; Wagih Benhassen; Guillaume Turc; Martin Bretzner; Marco Pasi; Joseph Benzakoun; Pierre Seners; Thomas Personnic; Laurence Legrand; Denis Trystram; Christine Rodriguez-Regent; Andreas Charidimou; Natalia S Rost; Serge Bracard; Frédéric Clarençon; Omer F Eker; Norbert Nighoghossian; Charlotte Cordonnier; Catherine Oppenheim; Olivier Naggara; Hilde Henon; Grégoire Boulouis
Journal:  J Neurol       Date:  2022-04-06       Impact factor: 6.682

6.  Effects of White Matter Hyperintensities on 90-Day Functional Outcome after Large Vessel and Non-Large Vessel Stroke.

Authors:  Christoph Johannes Griessenauer; David McPherson; Andrea Berger; Ping Cuiper; Nelson Sofoluke; Matthew D Adams; Saran Kunaprayoon; Ramin Zand; Jiang Li; Vida Abedi; Oded Goren; Clemens M Schirmer; Kathleen Donahue; Marco Nardin; Anne-Karin Giese; Markus D Schirmer; Natalia S Rost; Philipp Hendrix
Journal:  Cerebrovasc Dis       Date:  2020-07-21       Impact factor: 2.762

7.  Severe Cerebral Small Vessel Disease Burden Is Associated With Poor Outcomes After Endovascular Thrombectomy in Acute Ischemic Stroke With Large Vessel Occlusion.

Authors:  Destiny Hooper; Tariq Nisar; David McCane; Jason Lee; Ken Chyuan Ling; Farhaan Vahidy; Kelvin Wong; Stephen Wong; David Chiu; Rajan Gadhia
Journal:  Cureus       Date:  2021-02-04

Review 8.  Impact of leukoaraiosis severity on the association of outcomes of mechanical thrombectomy for acute ischemic stroke: a systematic review and a meta-analysis.

Authors:  Longwen Huo; Penghui Chen; Zhongxiu Wang; Xiandong Li; Jie Zhou; Chao Wang; Dajiang Xing; Shouchun Wang
Journal:  J Neurol       Date:  2020-08-28       Impact factor: 4.849

9.  Relationship of white matter lesion severity with early and late outcomes after mechanical thrombectomy for large vessel stroke.

Authors:  Zimbul Albo; Jose Marino; Muhammad Nagy; Dilip K Jayaraman; Muhammad U Azeem; Ajit S Puri; Nils Henninger
Journal:  J Neurointerv Surg       Date:  2020-05-15       Impact factor: 5.836

10.  White Matter Acute Infarct Volume After Thrombectomy for Anterior Circulation Large Vessel Occlusion Stroke is Associated with Long Term Outcomes.

Authors:  Robert W Regenhardt; Mark R Etherton; Alvin S Das; Markus D Schirmer; Joshua A Hirsch; Christopher J Stapleton; Aman B Patel; Thabele M Leslie-Mazwi; Natalia S Rost
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-12-29       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.